Cinclus Pharma Holding AB (OSTO:CINPHA) Long-Term Debt: kr0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:CINPHA Cinclus Pharma Holding AB OSTO:CINPHA
6 GF Score
Price kr12.04
! 3 Warning Signs
View Full Analysis

What is Cinclus Pharma Holding AB Long-Term Debt?

Cinclus Pharma Holding AB OSTO:CINPHA +0.67% 6 Long-Term Debt is kr0.00 Mil as of Mar. 2026. GuruFocus rates OSTO:CINPHA with a GF Score™ of 6/100. The stock has 3 warning signs investors should review.

Cinclus Pharma Holding AB's Long-Term Debt for the quarter that ended in Mar. 2026 was kr0.00 Mil.

Cinclus Pharma Holding AB  (OSTO:CINPHA) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Cinclus Pharma Holding AB Long-Term Debt Related Terms

Cinclus Pharma Holding AB Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Cinclus Pharma Holding AB's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cinclus Pharma Holding AB Long-Term Debt Chart

Cinclus Pharma Holding AB Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
0.00 0.00 0.00 0.00 0.00

Cinclus Pharma Holding AB Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
OSTO:CINPHA
6GF Score
Cinclus Pharma Holding AB OSTO:CINPHA
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of kr0.00 Mil mean?
Cinclus Pharma Holding AB (OSTO:CINPHA) has a Long-Term Debt of kr0.00 Mil as of Mar. 2026.
Is Cinclus Pharma Holding AB's Long-Term Debt too high?
Cinclus Pharma Holding AB's current Long-Term Debt is kr0.00 Mil. Overall, Cinclus Pharma Holding AB has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Cinclus Pharma Holding AB's Long-Term Debt compare to ZTS?
Cinclus Pharma Holding AB's Long-Term Debt of kr0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Cinclus Pharma Holding AB's current Long-Term Debt is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cinclus Pharma Holding AB stock overvalued right now?
Cinclus Pharma Holding AB (OSTO:CINPHA) has a current Long-Term Debt of kr0.00 Mil. The current Long-Term Debt is kr0.00 Mil. Cinclus Pharma Holding AB's overall GF Score™ is 6/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Cinclus Pharma Holding AB (OSTO:CINPHA), the current Long-Term Debt is kr0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cinclus Pharma Holding AB Business Description

Address Kungsbron 1, Stockholm, SWE, SE-111 22
Cinclus Pharma Holding AB is a Swedish clinical-stage pharmaceutical company focused on developing small-molecule treatments for gastric acid-related diseases. Its candidate, linaprazan glurate, is being developed for the treatment of severe gastroesophageal reflux disease, including erosive forms. The company is also developing a dual therapy treatment with an antibiotic targeting Helicobacter pylori, a bacterium found in the gastric and duodenal mucosa. Its primary target population consists of patients with severe erosive gastroesophageal reflux disease, where current treatment options are limited. It operates in Switzerland, Sweden, and the Czech Republic, with the majority of revenue from the Czech Republic.
6GF Score

Get the complete analysis for OSTO:CINPHA

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr12.04
Price